ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 338

Effect of Serum Urate Lowering with Allopurinol on Blood Pressure in Young Adults

Angelo Gaffo1, David Calhoun 2, Elizabeth Rahn 1, Suzanne Oparil 2, Peng Li 2, Tanja Dudenbostel 2, David Redden 2, Amy Mudano 2, Jeffrey Foster 1, Daniel Feig 2, Stephanie Biggers 2 and Kenneth Saag 1, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: allopurinol and cardiovascular disease, hypertension, hyperuricemia, uric acid

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 10, 2019

Session Title: Metabolic & Crystal Arthropathies Poster I: Clinical

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The association between serum urate and hypertension continues to be a matter of controversy.  Studies in adolescents provided evidence for the efficacy of urate lowering therapy to improve early hypertension, while at least one study in adults failed to find benefit. The Serum Uric acid Reduction to Prevent HypERtension (SURPHER) study tested whether serum urate reduction with allopurinol would lead to blood pressure reductions in pre-hypertensive young adults.

Methods: Single center, double-blinded, crossover trial in which participants were randomly assigned to allopurinol (300 daily mg) or placebo for a period of one month each separated by a 2-4 week washout. Adults ages 18-40 with baseline systolic blood pressure (SBP) ≥ 120 and < 160 mm Hg or diastolic blood pressure ≥ 80 and < 100 mm Hg, and serum urate ≥ 5.0 mg/dL for men or ≥ 4.0 mg/dL for women were enrolled. Main exclusion criteria included chronic kidney disease, gout, or use of urate-lowering therapies. The primary outcome was change from study treatment period baseline (allopurinol or placebo) in SBP assessed by 24 hour ambulatory blood pressure monitoring at four time points. Missing data was handled with a multiple imputation approach. Safety assessments were conducted as part of the study.

Results: 99 participants were randomized and 73 completed study participation. The characteristics of study participants are shown in Table 1. Serum urate decreased by 1.33 ± 1.21 mg/dL during the allopurinol period (p< 0.001) and by a non-significant 0.04 ± 0.75 mg/dL while taking placebo. SBP changed by -0.71 ± 8.21 mmHg during the period assigned to allopurinol versus -0.16 ± 7.33 mmHg during the period assigned to placebo.  The difference between these changes in SBP was not significant (p=0.52) (Table 2). Changes in diastolic blood pressure and mean ambulatory blood pressure also were not significantly different during allopurinol and placebo exposure periods. There was a trend to significant blood pressure decreases in the small participant subset with average serum urate of >6.5 mg/dL at the initiation of study periods (Figure). No allopurinol hypersensitivity events or other serious adverse events were observed.

Conclusion: In the intention-to-treat analysis urate-lowering therapy with allopurinol in young adults did not lead to reductions in blood pressure when compared with placebo. Blood pressure reductions were observed in participants with high baseline serum urate levels.

Table 1. Baseline characteristics of participants -n=99-

Table 2. Change in blood pressure parameters during allopurinol and placebo treatment phases -n=99-. Mean -SD-

Figure. Change in systolic blood pressure between allopurinol and placebo treatment phases in selected participant subgroups. BL = average baseline at the initiation of treatment phases -allopurinol and placebo-, BP= blood pressure, Compliant = any detectable oxypurinol at end of allopurinol phase


Disclosure: A. Gaffo, Amgen, 2; D. Calhoun, None; E. Rahn, None; S. Oparil, None; P. Li, None; T. Dudenbostel, None; D. Redden, None; A. Mudano, None; J. Foster, None; D. Feig, None; S. Biggers, None; K. Saag, Abbvie, 5, AbbVie, 5, Amgen, 2, 5, Ampel, 2, Bayer, 5, Gilead, 5, Horizon, 2, 5, Ironwood/AstraZeneca, 2, 5, Kowa, 5, kowa, 5, Mereo, 2, Radius, 5, Radius Health, 2, 5, Roche/Genentech, 5, SOBI, 2, 5, Sobi, 2, 5, Takeda, 2, 5, Teijin, 5, Tejin, 5.

To cite this abstract in AMA style:

Gaffo A, Calhoun D, Rahn E, Oparil S, Li P, Dudenbostel T, Redden D, Mudano A, Foster J, Feig D, Biggers S, Saag K. Effect of Serum Urate Lowering with Allopurinol on Blood Pressure in Young Adults [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/effect-of-serum-urate-lowering-with-allopurinol-on-blood-pressure-in-young-adults/. Accessed March 7, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-serum-urate-lowering-with-allopurinol-on-blood-pressure-in-young-adults/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.